1-4 of 4
Fred Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman
Journal: Diabetes Care
Diabetes Care 2014;37(10):2723–2730
https://doi.org/10.2337/dc13-2855
Published: 10 September 2014
View article titled, Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Open the PDF for Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study in another window
Includes: Supplementary data
Journal Articles

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Ahrén, Susan L. Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Journal: Diabetes Care
Diabetes Care 2014;37(8):2141–2148
https://doi.org/10.2337/dc14-0024
Published: 12 July 2014
View article titled, HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Open the PDF for HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin in another window
Includes: Supplementary data
Journal Articles

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter
Journal: Diabetes Care
Diabetes Care 2014;37(8):2317–2325
https://doi.org/10.2337/dc14-0001
Published: 12 July 2014
View article titled, Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Open the PDF for Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro in another window
Includes: Supplementary data
Journal Articles

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

Julio Rosenstock, MD, Jane Reusch, MD, Mark Bush, PHD, Fred Yang, PHD, Murray Stewart, DM, FRCP, for the Albiglutide Study Group
Journal: Diabetes Care
Diabetes Care 2009;32(10):1880–1886
https://doi.org/10.2337/dc09-0366
Published: 10 July 2009
View article titled, Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: <subtitle>A randomized controlled trial exploring weekly, biweekly, and monthly dosing</subtitle>
Open the PDF for Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: <subtitle>A randomized controlled trial exploring weekly, biweekly, and monthly dosing</subtitle> in another window
Includes: Supplementary data